Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Clinical trial NCT05886036 · RECRUITING

Trial details

NCT number: NCT05886036
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Nodular Lymphocyte Predominant B-Cell Lymphoma Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

Start date: 2024-01-23
Primary completion: 2026-10-31
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.